Investment Fund for Scotland and Macmillan Back Dxcover in £5M Growth Round
February 17, 2025
Dxcover, a University of Strathclyde spin-out developing multiomic, AI-enabled liquid biopsy diagnostics, raised £5 million from new and existing investors including the Investment Fund for Scotland (managed by Maven), Macmillan Cancer Support, Eos Advisory (lead), SIS Ventures, the University of Strathclyde and Norcliffe Capital. The funding will advance Dxcover's PANAROMIC platform technology, accelerate commercialisation of its brain cancer liquid biopsy and support expansion into the UK, Europe and the United States.
- Buyers
- Investment Fund for Scotland (IFS) / Maven, Macmillan Cancer Support, Eos Advisory, SIS Ventures, University of Strathclyde, Norcliffe Capital
- Targets
- Dxcover
- Industry
- Biotechnology
- Location
- Scotland, United Kingdom
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
IFS Maven Equity Finance Leads £2.2M Investment in Scotmas Group
January 15, 2025
Environmental Services
Scotmas Group, a B-Corp accredited chlorine dioxide water treatment specialist based in Kelso, has secured £2.2 million in growth capital led by IFS Maven Equity Finance with support from Scottish Enterprise and the British Business Bank. The funding will be used to accelerate international expansion (Middle East and South America), increase manufacturing capacity at the Kelso plant, and support product development and UK commercial/service team growth.
-
NPIF II (Maven) and Finance Durham Fund Back Magnitude Biosciences
May 27, 2025
Biotechnology
Magnitude Biosciences, a County Durham–based contract research organisation, secured over £700,000 in growth funding led by NPIF II - Maven Equity Finance alongside the Finance Durham Fund with continued support from Northstar Ventures. The funding, matched by an Innovate UK grant, will scale the company's WormGazer high-throughput in vivo screening platform, expand robotics, machine‑learning and biological capabilities, and create skilled jobs at NETPark in Sedgefield.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
Martis Capital Invests in DCN Dx
November 19, 2020
Medical Devices
Martis Capital has made a growth equity investment in DCN Dx, a Carlsbad, California-based lateral flow diagnostics developer and contract developer of rapid point-of-care tests. As part of the transaction, Charlie Mamrak will join DCN Dx as CEO; the capital will be used to accelerate growth and expand the company's diagnostic capabilities. Financial terms were not disclosed and Pegasus Capital and TM Capital advised on the deal.
-
Maverix Medical Acquires Cirrus Bio
March 29, 2024
Biotechnology
Maverix Medical, a lung cancer platform backed by Ajax Health, KKR, and Hologic, has acquired Cirrus Bio to form the foundation of a new diagnostics division, Maverix Dx. Cirrus Bio's multiomic diagnostic capabilities and its founders, David Mallery (CEO) and Scott Morris (CSO), will lead Maverix Dx as the platform pursues further diagnostic product development and M&A.
-
Strattam Capital Majority Growth Investment in Daxtra
June 28, 2023
AI & Machine Learning
Strattam Capital made a majority growth investment in The Daxtra Group, partnering with founders and co-owners Andrei Mikheev and Steven Finch. The investment will fund Daxtra's expansion in North America and accelerate adoption of its AI-enriched recruiting software and services.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.